Track market-moving stories before they get noisy

10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100

On September 08, 2026, 10x Genomics Inc TXG shares rose 4.7% today, bringing the current price to $65.61. The stock has seen significant volatility over the past year, with a 52-week range between $11.16 and $66.94.

GF Value™ verdict: Current price of $65.61 vs GF Value of $18.36, indicating a 257.4% overvaluation.GF Score™: 56/100, which is considered average.Notable signal: Insiders sold $10.2M worth of shares over the past 12 months, with no buying activity.Is TXG Overvalued or Undervalued?The GF Value™ estimate for 10x Genomics Inc is $18.36, suggesting that the current price of $65.61 is substantially overvalued by approximately 257.4%. This extreme reading should serve as a directional warning rather than a precise fair-value target. GF Value™ is GuruFocus' proprietary estimate of a stock's intrinsic value based on various factors, including historical trading multiples and future performance projections. Given that 10x Genomics is currently unprofitable and cash-flow negative, traditional earnings-based valuation methods such as Price-to-Earnings (P/E) ratios are not applicable. Instead, a Price-to-Sales (P/S) analysis may be more relevant, especially considering the company's historical median P/S ratio of approximately 10.3x.

With the stock trading at such a premium, the risk involved in holding shares is considerable. Investors must be cautious as it indicates a potentially inflated market sentiment that could lead to a price correction if the company's performance does not improve significantly.

How Does TXG's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)N/A~10.3x (historical median P/S)Since 10x Genomics does not currently have a meaningful P/E ratio due to its unprofitability, this analysis shifts focus to the Price-to-Sales metric. The company's historical P/S ratio of approximately 10.3x suggests that current valuations are significantly higher than historical averages, supporting the GF Value™ verdict of being overvalued.

What Does TXG's GF Score™ Tell Us?The GF Score™ evaluates a stock's overall quality, taking into account various factors such as financial strength, profitability, growth potential, valuation, and momentum. 10x Genomics has a GF Score™ of 56/100, indicating an average standing among its peers.

MetricRatingGF Score™56Financial Strength8/10Profitability3/10Growth6/10Valuation1/10Momentum3/10The scoring highlights that financial strength is a strong point, rated at 8/10, indicating a solid balance sheet. However, profitability is a significant weakness, with a score of just 3/10. The valuation rank is particularly concerning at 1/10, which aligns with the narrative of overvaluation based on GF Value™. The mixed results suggest that while the company has some strengths, particularly in financial stability, its profitability issues and poor valuation metrics warrant caution.

What Are Gurus and Insiders Doing with TXG?Currently, 9 gurus hold positions in 10x Genomics, with 3 increasing their stakes and 6 trimming their holdings in recent quarters. This indicates a divided sentiment among investment professionals. The lack of insider buying, coupled with the sale of $10.2M in shares by insiders over the past year, raises questions about the company's future prospects. Typically, insider selling can signal a lack of confidence in the company's near-term performance, making this a critical signal for potential investors to consider.

What This Means for InvestorsBased on the GF Value™ analysis, 10x Genomics Inc appears to be significantly overvalued at its current trading price of $65.61. With substantial insider selling and an average GF Score™, investors should proceed with caution. The risks associated with high valuations in the absence of profitability could lead to volatility and potential losses. For further details and insights, visit the 10x Genomics Inc TXG stock page for comprehensive data, including the GF Value™ page.

Frequently Asked QuestionsWhat is TXG's GF Score™?

TXG has a GF Score™ of 56/100, indicating an average quality ranking among its peers, suggesting a mixed outlook based on fundamental factors.

Is TXG overvalued or undervalued?

TXG is considered overvalued according to the GF Value™ verdict, which estimates its intrinsic value at $18.36 compared to the current price of $65.61.

What is TXG's P/E ratio?

TXG currently does not have a meaningful P/E ratio due to its unprofitability. Its historical median Price-to-Sales ratio is around 10.3x, indicating that current valuations are significantly higher than historical averages.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Key Takeaways 10x Genomics won over $4.8M after a jury found Parse willfully infringed three licensed patents.The jury upheld all three patents, reinforcing 10x Genomics' single-cell analysis IP portfolio.10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent U.S. injunction. 10x Genomics, Inc. (TXG - Free Report) recently secured a favorable jury verdict in its patent infringement case against Parse Biosciences, a Qiagen (QGEN - Free Report) subsidiary. The Delaware jury found Parse infringed three patents licensed to Scale Biosciences, upheld the patents' validity and awarded damages to TXG.

From an investor's perspective, the ruling reinforces 10x Genomics' intellectual property position in the single-cell analysis market and could support additional financial recovery through post-trial proceedings. Investors will likely watch whether the company secures enhanced damages or further protections for its technology in the U.S. market.

Likely Trend of TXG Stock Following the NewsHowever, following the announcement, shares of TXG slipped more than 5% on Friday. Year to date, shares of the company have surged 277.4% compared with the industry’s 11.4% growth. However, the S&P 500 has risen 12.3% in the same timeframe.

In the long run, the verdict could strengthen 10x Genomics' competitive position by reinforcing the value of its single-cell sequencing intellectual property portfolio, a key differentiator in the genomics market. If the company secures enhanced damages or a permanent injunction in post-trial proceedings, it could discourage future infringement, protect market share and support continued investment in innovation across its expanding single-cell and spatial biology businesses.

TXG currently has a market capitalization of $8.02 billion.

Image Source: Zacks Investment Research

Details of the NewsThe U.S. District Court for the District of Delaware found that Parse Biosciences, now a Qiagen subsidiary, willfully infringed three patents exclusively licensed to Scale Biosciences, which became part of 10x Genomics in 2025. The patents, originally licensed from Roche Sequencing Solutions, cover foundational single-cell analysis technologies. Importantly, the jury rejected Parse's invalidity arguments and upheld the validity and enforceability of all three patents, strengthening 10x Genomics' intellectual property portfolio in the fast-growing genomics space.  

The lawsuit centered on Parse's Evercode Whole Transcriptome products, with the jury concluding that infringing sales occurred from February 2021 through June 30, 2026. Based on a 14% royalty rate on those sales, the jury awarded more than $4.8 million in damages to 10x Genomics. The ruling follows a patent dispute that had been unfolding in Delaware federal court since 2022, making it one of the notable intellectual property battles in the single-cell sequencing market.

What's Next for Qiagen's Parse Business?The legal process is not over yet. In post-trial proceedings, 10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent injunction that would prevent Parse from continuing to sell the infringing products in the United States. For Qiagen, the next phase of the case could determine whether Parse must modify its U.S. product strategy, secure licensing arrangements or pursue additional legal options as the court considers the requested remedies.

Industry Prospects Favoring the MarketPer a report by Custom Market Insights, the global spatial biology market size is estimated at $1.48 billion in 2026 and is anticipated to reach $7.24 billion by 2035, expanding at a CAGR of 19.2% from 2026 to 2035.

Growth in spatial biology is driven by the rising demand for single-cell and tissue-level insights to better understand complex diseases like cancer. Expanding use in drug discovery, precision medicine and AI-driven research, along with advances in high-throughput sequencing technologies, is accelerating market adoption.

Other NewsRecently, 10x Genomics exited the second quarter of 2026 with better-than-expected results, as both earnings and revenues beat the Zacks Consensus Estimate. Reported revenues declined year over year due to lower non-recurring license and royalty revenues. However, the underlying business remained resilient. Products and Services revenues increased, supported by growth in Single Cell and Spatial consumables and higher services revenues. Gross margin expansion was another positive, although the company swung to an operating loss from year-ago operating income.

Atera remained the key development in the quarter. Customer response was strong, with booked orders at the end of the second quarter already well above the roughly 40 instruments previously expected for 2026. TXG continues to expect shipments of around 40 units this year as manufacturing capacity ramps. The company expects Atera-related transition dynamics to weigh on third-quarter revenues as customers moderate purchases of existing Spatial products.

TXG’s Zacks Rank & Key PicksCurrently, TXG has a Zacks Rank #3 (Hold).

A couple of better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire

PLEASANTON, Calif., Aug. 28, 2026

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge

, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are exclusively licensed from Roche Sequencing Solutions. The jury also rejected Parse's challenges to the validity of the patents, finding all three patents valid and enforceable.

"I started working on these inventions more than a decade ago and I'm incredibly proud of how they've expanded what's possible with single cell analysis," said Garry Nolan, PhD, co-founder of Scale Biosciences. "Today's verdict is a win for inventors. It affirms that original ideas matter and that strong patent rights are essential to advancing science."

"At Scale Bio, we executed on building high-quality technologies that changed what was possible for scientists," said Giovanna Prout, former CEO of Scale Biosciences. "Part of that was securing and investing in foundational intellectual property to protect our technology, enable further innovation and ensure that technology was respected by others in the industry. This is a critical part of what allows innovative companies to keep pushing science forward."

The jury awarded 10x over $4.8 million in damages for sales of Parse's infringing Evercode Whole Transcriptome products from February 2021 through June 30, 2026. The damages award is based on a 14% royalty rate on infringing Parse sales. In post-trial proceedings, 10x will seek additional awards including enhanced damages and attorneys' fees for Parse's willful infringement, and a permanent injunction stopping further infringement by Parse in the United States.

"The evidence presented at trial shows that Parse made a deliberate and calculated decision to ignore Dr. Nolan's seminal inventions in single cell analysis. The jury heard the evidence and soundly rejected Parse's defenses to find that Parse willfully infringed the patents exclusively licensed to Scale," said Randy Wu, General Counsel of 10x Genomics. "We are pleased with today's verdict, which makes clear that companies cannot simply benefit from the innovation of others and disregard the patent rights protecting them."

The patents adjudicated at trial are U.S. Patent Nos. 10,626,442, 10,982,256, and 11,512,341.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q for the fiscal quarter ended June 30, 2026 and 10-K for the fiscal year ended December 31, 2025 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts
Investors: [email protected]
Media: [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-wins-patent-infringement-verdict-against-parse-biosciences-302863074.html

SOURCE 10x Genomics, Inc.

Posted by Defense World Staff on Aug 13th, 2026

First Trust Advisors LP bought a new stake in 10x Genomics (NASDAQ:TXG – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 12,759 shares of the company’s stock, valued at approximately $271,000.

Several other large investors have also modified their holdings of the stock. Intech Investment Management LLC increased its holdings in 10x Genomics by 1.4% in the fourth quarter. Intech Investment Management LLC now owns 40,047 shares of the company’s stock valued at $653,000 after buying an additional 567 shares during the last quarter. Certuity LLC lifted its holdings in 10x Genomics by 4.7% during the 4th quarter. Certuity LLC now owns 20,204 shares of the company’s stock worth $330,000 after buying an additional 904 shares during the last quarter. Kera Capital Partners Inc. grew its position in shares of 10x Genomics by 2.3% in the 1st quarter. Kera Capital Partners Inc. now owns 48,937 shares of the company’s stock worth $1,039,000 after acquiring an additional 1,108 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of 10x Genomics by 28.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,660 shares of the company’s stock worth $92,000 after acquiring an additional 1,237 shares in the last quarter. Finally, M&T Bank Corp increased its holdings in shares of 10x Genomics by 6.3% in the 4th quarter. M&T Bank Corp now owns 21,699 shares of the company’s stock valued at $354,000 after acquiring an additional 1,282 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Insider Buying and Selling In other news, Director Shehnaaz Suliman sold 5,723 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $32.63, for a total transaction of $186,741.49. Following the completion of the transaction, the director owned 31,722 shares in the company, valued at approximately $1,035,088.86. This represents a 15.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 30,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $34.44, for a total transaction of $1,033,200.00. Following the transaction, the chief executive officer owned 1,108,380 shares of the company’s stock, valued at $38,172,607.20. This represents a 2.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 91,309 shares of company stock valued at $2,581,357 over the last three months. Corporate insiders own 8.84% of the company’s stock.

10x Genomics Trading Down 1.2% NASDAQ:TXG opened at $57.75 on Thursday. The stock has a 50 day moving average of $40.93 and a 200-day moving average of $28.43. The firm has a market capitalization of $7.33 billion, a PE ratio of -97.88 and a beta of 2.03. 10x Genomics has a 52 week low of $11.16 and a 52 week high of $60.69.

10x Genomics (NASDAQ:TXG – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.10. 10x Genomics had a negative return on equity of 9.41% and a negative net margin of 12.18%.The business had revenue of $151.04 million for the quarter, compared to the consensus estimate of $146.67 million. During the same quarter last year, the business posted $0.28 EPS. The business’s revenue was down 12.7% on a year-over-year basis. As a group, analysts predict that 10x Genomics will post -0.79 EPS for the current fiscal year.

Analysts Set New Price Targets Several equities research analysts recently issued reports on TXG shares. Morgan Stanley upped their price target on 10x Genomics from $37.00 to $40.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 10x Genomics in a report on Wednesday, June 24th. Stifel Nicolaus set a $50.00 target price on shares of 10x Genomics in a research note on Friday, August 7th. Canaccord Genuity Group increased their target price on shares of 10x Genomics from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Monday. Finally, Piper Sandler raised their price target on shares of 10x Genomics from $42.00 to $47.00 and gave the stock a “neutral” rating in a research report on Monday. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $38.31.

Check Out Our Latest Stock Report on TXG

About 10x Genomics (Free Report)

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.

Featured Stories Five stocks we like better than 10x Genomics GE Vernova’s AI Power Boom Faces a Profit Test Cardinal Health Earnings: Can Perfection Get Priced In Twice? Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Legacy Jet Builders Stall While Embraer Accelerates to New Highs Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG – Free Report).

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEKosmos Energy Ltd. $KOS Shares Purchased by California State Teachers Retirement System

NEXT HEADLINE »California State Teachers Retirement System Has $1.76 Million Stock Holdings in USA Rare Earth Inc. $USAR

Key Takeaways TXG beat Q2 earnings and revenue estimates despite a 12.6% year-over-year revenue decline.TXG's gross margin expanded 200 basis points to 74%, helped by lower manufacturing costs and write-downs.TXG raised its 2026 revenue guidance to $610 million-$630 million from $600 million-$625 million. 10x Genomics (TXG - Free Report) reported a second-quarter 2026 loss of 14 cents per share against earnings of 28 cents in the year-ago quarter, representing a 150% year-over-year decline. Still, the figure beat the Zacks Consensus Estimate of a loss of 23 cents by 38.1%.

Revenues of $151 million declined 12.6% year over year but surpassed the Zacks Consensus Estimate of $146.9 million by 2.8%. Excluding non-recurring patent litigation settlement revenues in both periods, revenues increased 3%.

Shares of TXG lost 5% in yesterday’s after-market trading. The company’s shares have surged 194% in the year-to-date period against the industry’s decrease of 6.5%. However, the broader S&P 500 Index has increased 12.4% in the same time frame.

Image Source: Zacks Investment Research

TXG's Consumables Business Maintains MomentumProducts and services revenues totaled $149.1 million, up 2.7% year over year. Total consumables revenues were $130.8 million, with Single Cell consumables increasing 3.1% year over year to $88.5 million and Spatial consumables rising 16.2% to $42.3 million.

Total instrument revenues declined 47.2% year over year to $7.7 million. Single Cell instrument revenues fell 46.1% year over year to $3.1 million, while Spatial instrument revenues dropped 47.8% to $4.6 million.  

Management noted that the decline in Spatial instruments reflected customers moderating purchases of existing products ahead of the Atera launch.

Services revenues increased 26% year over year to $10.7 million.  

10x Genomics' Regional Performance Stays MixedTotal Americas revenues were $85 million, down 19.9% from the prior-year quarter. However, excluding non-recurring license and royalty revenues in both periods, Americas revenues increased 6% year over year, indicating better underlying performance than the reported comparison suggests.  

EMEA revenues rose 15.1% year over year to $39.9 million.

Asia-Pacific revenues declined 18.7% year over year to $26 million. Management noted that the prior-year Asia-Pacific results benefited from roughly $4 million of purchasing activity pulled forward in China ahead of potential tariff changes.  

TXG's Margin TrendIn the quarter under review, TXG’s gross profit declined 10.1% year over year to $112.5 million. However, the gross margin expanded 200 basis points (bps) to 74%, primarily driven by lower manufacturing costs, including $2.6 million of tariff refunds and lower inventory write-downs.

Selling, general and administrative expenses increased 5.7% year over year to $78.7 million. Research and development expenses declined 7.2% year over year to $56.8 million. Total operating expenses of $132.1 million increased 39.1% year over year, mainly due to a lower gain on settlement compared with the prior-year quarter. Excluding settlement gains, operating expenses were approximately flat year over year.

Total operating loss was $19.6 million against an operating income of $30.1 million in the year-ago quarter.

TXG’s Financial PositionTXG exited the second quarter of 2026 with cash, cash equivalents and marketable securities of $552 million, up from $539.8 million at the end of the first quarter of 2026. Importantly, the company ended the quarter with no debt on its balance sheet, underscoring a solid solvency position.

10x Genomics Raises Its 2026 Revenue OutlookThe company raised its 2026 revenue guidance to $610 million-$630 million from the prior range of $600 million-$625 million. Excluding non-recurring patent litigation settlement revenues in both 2026 and 2025, the updated outlook represents growth of 2% to 5% over 2025.

Management attributed the increase to first-half performance and the $1.6 million of settlement revenue recognized during the second quarter. The outlook assumes that the broader academic funding environment remains roughly consistent with recent conditions, leaving potential improvement in funding outside the company's current guidance assumptions.

Wrapping Up10x Genomics exited the second quarter of 2026 with better-than-expected results, as both earnings and revenues beat the Zacks Consensus Estimate. Reported revenues declined year over year due to lower non-recurring license and royalty revenues. However, the underlying business remained resilient. Products and Services revenues increased, supported by growth in Single Cell and Spatial consumables and higher services revenues. Gross margin expansion was another positive, although the company swung to an operating loss from year-ago operating income.

Atera remained the key development in the quarter. Customer response was strong, with booked orders at the end of the second quarter already well above the roughly 40 instruments previously expected for 2026. TXG continues to expect shipments of around 40 units this year as manufacturing capacity ramps. The company expects Atera-related transition dynamics to weigh on third-quarter revenues as customers moderate purchases of existing Spatial products. A significant sequential revenue increase is expected in the fourth quarter as Atera shipments begin contributing more meaningfully.

TXG also strengthened its multiomics and diagnostics strategy during the quarter. The company acquired Proteintech Genomics, adding advanced protein-detection capabilities to its Single Cell and Spatial platforms. It also announced multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital to advance diagnostic applications in cancer care. Meanwhile, TXG ended the quarter with $552 million in cash, cash equivalents and marketable securities, providing financial flexibility to support product development and commercialization efforts.

TXG’s Zacks Rank and Stocks to ConsiderTXG currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .

McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

McKesson shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.

Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.

Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.

Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.

Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.

10x Genomics (TXG - Free Report) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +39.13%. A quarter ago, it was expected that this life science technology company would post a loss of $0.29 per share when it actually produced a loss of $0.1, delivering a surprise of +65.52%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

10x Genomics, which belongs to the Zacks Medical Info Systems industry, posted revenues of $151.04 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.77%. This compares to year-ago revenues of $172.91 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

10x Genomics shares have added about 191% since the beginning of the year versus the S&P 500's gain of 12.8%.

What's Next for 10x Genomics?While 10x Genomics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for 10x Genomics was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.26 on $147.49 million in revenues for the coming quarter and -$0.78 on $614.51 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, MDxHealth SA (MDXH - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13.

This company is expected to post quarterly loss of $0.12 per share in its upcoming report, which represents a year-over-year change of +20%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

MDxHealth SA's revenues are expected to be $25.8 million, down 3% from the year-ago quarter.

, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the second quarter ended June 30, 2026.

Recent Updates

Revenue was $151.0 million for the second quarter of 2026. Excluding $1.6 million related to a patent litigation settlement, revenue was $149.4 million. Revenue increased 3% over the corresponding period of 2025 when excluding non-recurring settlement revenue in both the current and prior-year periods. Acquired Proteintech Genomics, a division within Proteintech Group, strengthening the company's multiomics strategy by adding advanced protein detection capabilities to its single cell and spatial platforms. Announced multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital to advance research in diagnostic applications of single cell and spatial technologies for cancer care, furthering the company's diagnostics strategy. "The story of the quarter was the extraordinary customer response to Atera. We are highly encouraged by the engagement across the research ecosystem and the very strong early order flow," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Combined with the continued momentum across the rest of the business and our strong operating foundation, we are uniquely well-positioned for the opportunities ahead."

Second Quarter 2026 Financial Results

Revenue was $151.0 million for the second quarter of 2026, as compared to $172.9 million for the corresponding period of 2025. Excluding $1.6 million and $27.3 million of non-recurring revenue related to patent litigation settlements in the second quarter of 2026 and 2025, respectively, revenue increased 3% over the corresponding period of 2025.

Gross margin was 74% for the second quarter of 2026, as compared to 72% for the corresponding prior year period. The increase in gross margin was primarily due to lower manufacturing costs, which included $2.6 million of tariff refunds, as well as lower inventory write-downs, partially offset by a decrease in non-recurring license and royalty revenue.

Operating expenses were $132.1 million for the second quarter of 2026, a 39% increase from $95.0 million for the corresponding prior year period. The increase was primarily due to a lower gain on settlement of $3.4 million recognized in the second quarter of 2026, as compared to a $40.7 million gain on settlement recognized in the second quarter of 2025. Excluding impacts from settlements, operating expenses were approximately flat year-over-year.

Operating loss was $19.6 million for the second quarter of 2026, as compared to operating income of $30.1 million for the corresponding prior year period.

Net loss was $17.9 million for the second quarter of 2026, as compared to net income of $34.5 million for the corresponding prior year period.

Cash and cash equivalents and marketable securities were $552.0 million as of June 30, 2026.

2026 Financial Guidance 

10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, versus the previous range of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 2% to 5% growth over full year 2025.

Webcast and Conference Call Information

10x Genomics will host a conference call to discuss the second quarter 2026 financial results, business developments and outlook after market close on Thursday, August 6, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "outlook," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities and 10x Genomics, Inc.'s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company's quarterly report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the U.S. Securities and Exchange Commission ("SEC"), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

Investors: [email protected]

Media: [email protected]

10x Genomics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended
June 30,

Six Months Ended
June 30,

2026

2025

2026

2025

Products and services revenue

$      149,094

$      145,157

$      298,990

$      282,980

License and royalty revenue

1,942

27,751

2,889

44,811

Revenue (1)

151,036

172,908

301,879

327,791

Cost of products and services revenue (2)

38,539

47,824

83,204

97,262

Gross profit

112,497

125,084

218,675

230,529

Operating expenses:

Research and development (2)

56,791

61,224

113,638

125,469

Selling, general and administrative (2)

78,661

74,434

145,038

164,162

Gain on settlement

(3,400)

(40,700)

(3,400)

(49,900)

Total operating expenses

132,052

94,958

255,276

239,731

Income (loss) from operations

(19,555)

30,126

(36,601)

(9,202)

Other income (expense):

Interest income

4,797

4,271

9,811

7,957

Interest expense

—

(3)

—

(3)

Other income (expense), net

(3,887)

2,603

(4,702)

4,739

Total other income

910

6,871

5,109

12,693

Income (loss) before provision for income taxes

(18,645)

36,997

(31,492)

3,491

Provision for (benefit from) income taxes

(714)

2,459

(91)

3,311

Net income (loss)

$     (17,931)

$       34,538

$      (31,401)

$           180

Net income (loss) per share, basic

$         (0.14)

$           0.28

$          (0.24)

$0.00

Net income (loss) per share, diluted

$         (0.14)

$           0.28

$          (0.24)

$0.00

Weighted-average shares used to compute net income
(loss) per share, basic

129,984,169

123,755,409

129,050,312

123,183,924

Weighted-average shares used to compute net income
(loss) per share, diluted

129,984,169

124,509,720

129,050,312

124,258,150

(1)

 The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium and Xenium products:

Three Months Ended
June 30,

Six Months Ended
June 30,

2026

2025

2026

2025

Instruments

Single Cell

$        3,087

$        5,727

$         8,310

$       11,640

Spatial

4,574

8,770

$       10,613

17,672

Total instruments revenue

7,661

14,497

18,923

29,312

Consumables

Single Cell

88,451

85,788

177,345

169,897

Spatial

42,301

36,397

83,208

67,644

Total consumables revenue

130,752

122,185

260,553

237,541

Services

10,681

8,475

19,514

16,127

Products and services revenue

149,094

145,157

$      298,990

$      282,980

License and royalty revenue

1,942

27,751

$          2,889

$        44,811

Total revenue

$      151,036

$      172,908

$      301,879

$      327,791

(1)

 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

Three Months Ended
June 30,

Six Months Ended
June 30,

2026

2025

2026

2025

Americas

United States*

$       82,109

$      103,491

$      158,802

$      190,309

Americas (excluding United States)

2,917

2,667

$          6,323

6,419

Total Americas

85,026

106,158

165,125

196,728

Europe, Middle East and Africa

39,972

34,734

76,824

66,629

Asia-Pacific

China

14,968

23,170

30,805

40,053

Asia-Pacific (excluding China)

11,070

8,846

29,125

24,381

Total Asia-Pacific

26,038

32,016

59,930

64,434

Total revenue

$      151,036

$      172,908

$      301,879

$      327,791

* Includes license and royalty revenue.

(2)

 Includes stock-based compensation expense as follows:

Three Months Ended
June 30,

Six Months Ended
June 30,

(in thousands)

2026

2025

2026

2025

Cost of revenue

$         1,836

$         1,989

$         3,754

$         4,470

Research and development

10,533

12,613

21,228

26,719

Selling, general and administrative

13,247

12,643

23,276

27,132

Total stock-based compensation expense

$       25,616

$       27,245

$       48,258

$       58,321

10x Genomics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)

June 30,
2026

December 31,
2025

Assets

Current assets:

Cash and cash equivalents

$      502,512

$      473,966

Marketable securities

49,521

49,443

Accounts receivable, net

47,545

47,013

Other receivables

3,084

35,480

Inventory

52,616

56,341

Prepaid expenses and other current assets

19,393

22,208

Total current assets

674,671

684,451

Property and equipment, net

215,324

226,711

Operating lease right-of-use assets

56,685

60,450

Goodwill

6,918

4,511

Intangible assets, net

61,160

62,329

Other noncurrent assets

15,308

2,913

Total assets

$   1,030,066

$   1,041,365

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$       20,694

$       12,733

Accrued compensation and related benefits

24,744

42,500

Accrued expenses and other current liabilities

30,377

39,971

Deferred revenue

23,610

23,902

Operating lease liabilities

12,015

10,985

Contingent consideration, current

7,069

23,363

Total current liabilities

118,509

153,454

Contingent consideration, noncurrent

2,991

1,237

Operating lease liabilities, noncurrent

66,781

73,376

Deferred revenue, noncurrent

9,683

10,501

Other noncurrent liabilities

6,556

6,471

Total liabilities

204,520

245,039

Stockholders' equity:

Preferred stock

—

—

Common stock

2

2

Additional paid-in capital

2,367,459

2,306,690

Accumulated deficit

(1,541,992)

(1,510,591)

Accumulated other comprehensive income

77

225

Total stockholders' equity

825,546

796,326

Total liabilities and stockholders' equity

$   1,030,066

$   1,041,365

SOURCE 10x Genomics, Inc.

Wall Street expects a year-over-year decline in earnings on lower revenues when 10x Genomics (TXG - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis life science technology company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of -182.1%.

Revenues are expected to be $146.96 million, down 15% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.73% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for 10x Genomics?For 10x Genomics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +10.93%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that 10x Genomics will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that 10x Genomics would post a loss of$0.29 per share when it actually produced a loss of -$0.10, delivering a surprise of +65.52%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

10x Genomics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerCarlsmed, Inc. (CARL - Free Report) , another stock in the Zacks Medical Info Systems industry, is expected to report loss per share of $0.4 for the quarter ended June 2026. This estimate points to a year-over-year change of +72.8%. Revenues for the quarter are expected to be $18.52 million, up 53.3% from the year-ago quarter.

The consensus EPS estimate for Carlsmed, Inc. has remained unchanged over the last 30 days. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -18.99%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Carlsmed, Inc. will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. cut its holdings in shares of 10x Genomics (NASDAQ:TXG – Free Report) by 7.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,104,178 shares of the company’s stock after selling 381,975 shares during the period. 10x Genomics comprises about 1.5% of Amova Asset Management Americas Inc.’s portfolio, making the stock its 18th biggest position. Amova Asset Management Americas Inc. owned about 4.00% of 10x Genomics worth $108,311,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Geneos Wealth Management Inc. acquired a new position in shares of 10x Genomics in the fourth quarter valued at approximately $38,000. Larson Financial Group LLC boosted its position in 10x Genomics by 164.4% in the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after buying an additional 1,470 shares during the period. Fifth Third Bancorp acquired a new position in shares of 10x Genomics in the first quarter worth $50,000. Van ECK Associates Corp grew its stake in shares of 10x Genomics by 85.9% in the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after acquiring an additional 1,695 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of 10x Genomics by 203.9% during the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after acquiring an additional 5,025 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth TXG has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a report on Wednesday, June 24th. Canaccord Genuity Group increased their price target on 10x Genomics from $32.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Bank of America boosted their price objective on 10x Genomics from $21.00 to $30.00 and gave the stock a “neutral” rating in a research report on Monday, April 20th. Leerink Partners upped their target price on shares of 10x Genomics from $23.00 to $40.00 and gave the stock a “market perform” rating in a research note on Friday. Finally, Morgan Stanley raised their target price on shares of 10x Genomics from $22.00 to $37.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, 10x Genomics has a consensus rating of “Hold” and an average price target of $32.08.

Check Out Our Latest Stock Analysis on 10x Genomics

Insider Activity at 10x Genomics In other 10x Genomics news, CEO Serge Saxonov sold 30,000 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $34.44, for a total value of $1,033,200.00. Following the completion of the transaction, the chief executive officer owned 1,108,380 shares in the company, valued at $38,172,607.20. This represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Shehnaaz Suliman sold 5,723 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $32.63, for a total value of $186,741.49. Following the transaction, the director directly owned 31,722 shares in the company, valued at approximately $1,035,088.86. The trade was a 15.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 91,309 shares of company stock valued at $2,581,357 in the last ninety days. 8.84% of the stock is currently owned by insiders.

10x Genomics Stock Down 1.2% Shares of 10x Genomics stock opened at $43.22 on Tuesday. 10x Genomics has a 52 week low of $11.16 and a 52 week high of $46.32. The firm’s 50 day moving average is $32.61 and its two-hundred day moving average is $24.90. The firm has a market capitalization of $5.49 billion, a P/E ratio of -254.24 and a beta of 2.05.

10x Genomics (NASDAQ:TXG – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.19. The business had revenue of $150.84 million during the quarter, compared to the consensus estimate of $146.41 million. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.28) EPS. As a group, research analysts expect that 10x Genomics will post -0.79 earnings per share for the current fiscal year.

10x Genomics Company Profile (Free Report)

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.

Recommended Stories Five stocks we like better than 10x Genomics The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc.

NEXT HEADLINE »Tempus AI, Inc. $TEM Stake Boosted by Amova Asset Management Americas Inc.

, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

Investors: [email protected]

Media: [email protected]

SOURCE 10x Genomics, Inc.

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms

, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.

This collaboration is part of 10x's broader efforts to partner with leading research institutions to generate the evidence needed to support the future development of diagnostic applications across oncology and other disease areas.

Through this multi-year collaboration, the study intends to initially examine tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens using 10x's Flex Apex and Xenium platforms, with the goal of expanding to the recently announced Atera platform. The research aims to identify clinically relevant biomarkers that may help predict bladder cancer patient response to treatment and support future diagnostic development across tumor types.

Bladder cancer remains a complex and heterogeneous disease, with variable responses to therapies such as antibody-drug conjugates and immunotherapies. A major challenge in oncology is determining which therapies are most likely to benefit individual patients. By integrating single cell and spatial analysis, the research aims to generate a more comprehensive understanding of tumor biology and the tumor microenvironment, including features that may influence treatment response and resistance, which remain difficult to characterize using conventional approaches.

"We look forward to collaborating with 10x Genomics on this promising work. This collaboration has the potential to shed new light into the mechanisms underlying therapeutic response in a number of major cancer types," said Timothy Chan, MD, PhD, Chair, Department of Cancer Sciences, Cleveland Clinic.

The study is expected to include tumor samples from patients treated with antibody-drug conjugates and immunotherapy and to integrate single-cell transcriptomic profiling, spatial gene expression and protein measurements. Researchers plan to analyze tumor microenvironment composition, immune cell infiltration and expression of therapeutic targets to better understand mechanisms of response and resistance.

"One of the central challenges in oncology today is understanding why patients respond differently to the same therapy," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "There is a clear need for biomarkers that can guide treatment decisions, and we believe Flex Apex, Xenium and now Atera are uniquely suited to uncover them. These insights will be critical to enabling a new generation of diagnostic approaches in oncology."

The collaboration is expected to generate a comprehensive, multimodal dataset linking single cell and spatial insights with clinical outcomes, helping to advance the scientific understanding of treatment response in bladder cancer and support future diagnostic applications.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Contacts
Investors: [email protected]
Media: [email protected]

SOURCE 10x Genomics, Inc.

Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) announces the results of its 2026 annual and special meeting of shareholders (the "Meeting") held virtually today.

The Meeting marked the retirement of Jody Kuzenko and the formal appointment of Andrew Snowden as President and CEO of the Company. Mr. Snowden was also elected to the Board of Directors along with the re-election of seven current Directors, as well as the re-appointment of Rick Howes as Chair of the Board.

Rick Howes, Chair of the Board of Torex, stated:

"On behalf of the Board of Directors and everyone at the Company, I want to extend my sincere appreciation to Jody for her exceptional leadership at Torex over the past eight years. Jody leaves the business in an excellent position for the next chapter of growth and success, and we wish her all the very best as she steps into her well-deserved retirement.

"The Board looks forward to working with Andrew in his new role as President and CEO as we continue to execute on our strategic pillars to build one of the best mining companies in the industry as a diversified, Americas-focused precious metals producer.

"Finally, to our shareholders, thank you for your ongoing trust and support. We are firmly committed to seizing the many opportunities ahead in order to continue to generate significant and lasting value for those who choose to invest in us."

ITEM 1. ELECTION OF DIRECTORS
At the Meeting, all director nominees listed in the Company's management information circular (the "Circular") dated May 6, 2026, were elected as directors of the Company. Detailed results of the vote by ballot are as follows:

DIRECTORVOTE TYPENUMBER OF VOTES% OF VOTESRichard A. HowesFor
Withheld73,557,809
69,57399.91%
0.09%Andrew SnowdenFor
Withheld73,616,975
10,40799.99%
0.01%Caroline DonallyFor
Withheld73,035,733
591,64999.20%
0.80%Jennifer J. HooperFor
Withheld73,209,711
417,67199.43%
0.57%Jay C. KellermanFor
Withheld72,793,419
833,96398.87%
1.13%Rosalie C. MooreFor
Withheld73,587,235
40,14799.95%
0.05%Rodrigo SandovalFor
Withheld72,915,027
712,35599.03%
0.97%Jacques PerronFor
Withheld73,587,700
39,68299.95%
0.05%ITEM 2. APPOINTMENT OF AUDITOR
On a vote by ballot, KPMG LLP, Chartered Professional Accountants, were re-appointed as auditors of the Company, and the directors were authorized to fix their remuneration.

VOTES FOR % VOTES FORVOTES WITHHELD% OF VOTES WITHHELD74,711,61898.74%955,6051.26%ITEM 3. APPROVAL OF NAME CHANGE
On a vote by ballot, a special resolution was passed authorizing and approving an amendment to the articles of the Company to change the name of the Company to "Torex Resources Inc.", or such other name as the Board of Directors of the Company, in its sole discretion, may approve, subject to regulatory approval. The Company expects to officially adopt the Company's new name later this year.

VOTES FOR % VOTES FORVOTES AGAINST% OF VOTES AGAINST75,467,15999.74%200,0650.26%ITEM 4. 'SAY ON PAY' EXECUTIVE COMPENSATION
On a vote by ballot, a non-binding advisory resolution was passed accepting the approach to executive compensation disclosed in the Circular and delivered in advance of the Meeting.

VOTES FOR % VOTES FORVOTES AGAINST% OF VOTES AGAINST71,129,95696.61%2,497,4263.39%The formal report on voting results with respect to all matters voted upon at the Meeting will be filed on SEDAR+ at http://www.sedarplus.ca/.

ABOUT TOREX GOLD RESOURCES INC.
Torex Gold Resources Inc. is a Canadian mining company engaged in the exploration, development, and production of gold, copper, and silver from its flagship Morelos Complex in Guerrero, Mexico. The Company also owns the Los Reyes gold-silver project in Sinaloa and a portfolio of early-stage exploration properties, including the Batopilas and Guigui projects in Chihuahua, Mexico, and the Medicine Springs project in Nevada, USA as well as an option to acquire the Gryphon project in Nevada, USA.

The Company's key strategic objectives are: optimize Morelos production and costs; disciplined growth and capital allocation; grow reserves and resources; project delivery excellence; retain and attract best industry talent; and be an industry leader in responsible mining. In addition to realizing the full potential of the Morelos Property, the Company continues to seek opportunities to acquire assets that enable diversification and deliver value to shareholders.

CAUTIONARY NOTES ON FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding the change of the Company's name; and the Company's key strategic objectives: optimize Morelos production and costs; disciplined growth and capital allocation; grow reserves and resources; project delivery excellence; retain and attract best industry talent; and be an industry leader in responsible mining. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "continue", "strategy" and "ongoing" or variations of such words. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including, without limitation, those risk factors identified in the Company's annual information form ("AIF") and management's discussion and analysis ("MD&A"). Forward-looking information is based on the assumptions discussed in the AIF and MD&A and such other reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances at the date such statements are made. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be as anticipated. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, whether as a result of new information or future events or otherwise, except as may be required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301919

Source: Torex Gold Resources Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Hinge Health (NYSE:HNGE – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Profitability This table compares Hinge Health and 10x Genomics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Hinge Health N/A N/A N/A 10x Genomics -6.77% -6.89% -5.34% Analyst Ratings This is a breakdown of recent ratings and target prices for Hinge Health and 10x Genomics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hinge Health 1 1 16 1 2.89 10x Genomics 2 10 5 0 2.18 Hinge Health currently has a consensus price target of $56.73, indicating a potential upside of 36.71%. 10x Genomics has a consensus price target of $19.46, indicating a potential downside of 23.22%. Given Hinge Health’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Hinge Health is more favorable than 10x Genomics.

Earnings & Valuation This table compares Hinge Health and 10x Genomics”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hinge Health $587.86 million 5.56 -$528.26 million ($12.81) -3.24 10x Genomics $642.82 million 5.04 -$43.54 million ($0.35) -72.43 10x Genomics has higher revenue and earnings than Hinge Health. 10x Genomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership 84.7% of 10x Genomics shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary Hinge Health beats 10x Genomics on 9 of the 14 factors compared between the two stocks.

About Hinge Health (Get Free Report)

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation. Members receive personalized and largely automated MSK care through our AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device, all designed and monitored by our AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Our platform can improve pain and function and reduce the need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere and embrace movement as a way of life. There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other industries, the launch of new technologies has generally improved end-user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe there are two key reasons for healthcare’s idiosyncratic response to technology: • Automating most aspects of care is difficult because so many healthcare interventions involve unstructured physical tasks. • The current framework for healthcare reimbursement has specific pathways to pay for care, which means new technologies are constrained to deliver within this framework. At Hinge Health, we have taken these challenges head-on. To address the automation of care, we have weaved together AI-enabled capabilities – such as our AI-powered motion tracking technology, TrueMotion, our proprietary FDA-cleared wearable device, Enso, and our AI-supported care team – to deliver scalable and personalized MSK care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. We have done this while improving our high member satisfaction over time. To address healthcare reimbursement constraints, we developed novel billing methods for our innovative technology by both directly selling to employers while also partnering with health plans, pharmacy benefit managers (“PBMs”), third-party administrators (“TPAs”), and other ecosystem entities to efficiently provide our platform to clients and members. While the MSK market is massive, existing solutions have fallen short as they are often expensive, ineffective, inconvenient to access, and delivered in a one-to-one or few-to-one care setting. Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to be simple and accessible, complete, personalized, and scalable. • Simple and accessible: We provide members access to our platform at no direct cost to them and without a copay or deductible. Members can access our broad spectrum of MSK care through a single on-demand app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses. Potential members can complete a simple intake form, download the app, and start exercises soon thereafter. During the year ended December 31, 2024, approximately 64% of members were onboarded on the same day they completed their intake form, and approximately 75% of members were onboarded within the first week. • Complete: Our platform offers a wide range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer non-addictive and non-invasive pain relief via electrostimulation through our proprietary FDA-cleared wearable device, Enso, that is seamlessly integrated into our platform. • Personalized: Our platform delivers smarter care through AI and machine learning. Our AI model is trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of March 31, 2025, we had treated over one million members and our programs had tracked over 74 million activity sessions and 32 million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time in-app exercise feedback based on the member’s input and our proprietary motion tracking technology. • Scalable: Our AI-powered motion tracking technology, TrueMotion, allows us to deliver scalable and largely automated care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. While most of our programs provide members with access to a dedicated care team, our technology automates most aspects of care delivery while allowing our members to progress through their exercise therapy sessions on their own time. We have developed an efficient go-to-market model by working directly with our partners and clients. We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. Our clients are primarily self-insured employers and include many of the nation’s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and labor unions. In most instances, we partner with clients’ health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, procurement, security and IT reviews, onboarding, and billing. We are also in the early stages of expanding to serve health plans’ fully-insured and Medicare Advantage populations and federal insurance plans. As of December 31, 2024, we had approximately 20 million contracted lives across more than 2,250 clients. We had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies, as of December 31, 2024. Despite this progress, our current contracted lives only represent 5% of our total addressable market. We believe that we grow efficiently because of our scalable, repeatable go-to-market model. We sell through our direct sales force and our partners. Once we contract with a client, we are most often the sole digital MSK care provider offered to their contracted lives. Our average contract term is three years. For the term of each contract, we are able to enroll, engage, and re-engage the client’s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated in our net dollar retention of 117% as of December 31, 2024. Our 12-month client retention rate was 98% as of December 31, 2024. Additionally, we have a high level of client satisfaction, as shown by our client net promoter score (“NPS”) of 87 as of October 31, 2024. We also invested early in building our partner network. As of March 31, 2025, we had over 50 partners. Our partners include the five largest national health plans by self-insured lives, and the top three PBMs by market share. As of that date, we had retained 100% of our partners that we chose to work with since inception, excluding partners who were acquired. We have experienced significant growth since our inception, with a recurring revenue business model. As of December 31, 2024, we had over 532,000 members and more than 2,250 clients, compared to approximately 371,000 members and approximately 1,650 clients as of December 31, 2023. Our principal executive offices are located in San Francisco, California.

About 10x Genomics (Get Free Report)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Receive News & Ratings for Hinge Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hinge Health and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways 10x Genomics unveiled Atera, a spatial biology platform for whole-transcriptome analysis at scale.Atera removes tradeoffs in scale, sensitivity and coverage, boosting appeal in research and drug discovery.Early adoption and partnerships signal demand, supporting TXG's growth in spatial biology markets. 10x Genomics (TXG - Free Report) recently unveiled Atera, a next-generation in situ spatial biology platform designed to deliver whole-transcriptome analysis with single-cell sensitivity at scale. Unveiled at the American Association for Cancer Research Annual Meeting 2026, the launch highlights TXG’s continued push to advance how researchers study complex biological systems within intact tissue environments.

The new platform aims to overcome long-standing tradeoffs in spatial biology, positioning TXG to tap into growing demand across translational research and drug discovery. Early adoption by leading research institutions and service providers signals strong interest, reinforcing the company’s innovation-driven growth narrative and long-term opportunity in high-throughput spatial analysis.

Likely Trend of TXG Stock Following the NewsShares of TXG have gained 3.3% since the announcement of the launch. In the year-to-date period, shares of the company gained 59.9% against the industry’s 19.1% decline.  The S&P 500 increased 4.2% in the same time frame.

The Atera launch can meaningfully strengthen 10x Genomics’ long-term business by expanding its total addressable market and deepening its moat in spatial biology. By eliminating tradeoffs between scale, sensitivity and gene coverage, Atera positions TXG as a go-to platform for large-scale, high-resolution studies, attracting biopharma, academic and clinical customers. This should drive higher instrument placements, recurring consumables revenue and growing adoption of its cloud-based analysis ecosystem. Over time, stronger integration into drug discovery workflows and large consortium projects could enhance visibility, create sticky customer relationships and support durable revenue growth.

TXG currently has a market capitalization of $3.33 billion.

Image Source: Zacks Investment Research

More on the NewsFrom a technology and infrastructure standpoint, Atera reflects a ground-up redesign of spatial analysis, integrating advances across chemistry, hardware and software to remove longstanding limitations. To complement the platform, TXG is introducing a new cloud-based analysis solution that enables secure data storage, visualization and GPU-accelerated processing, significantly reducing time from raw data to insight.

Researchers can maintain full control over workflows through flexible deployment options, including cloud and on-premise environments. Additionally, the company has launched Catalyst Research Services, allowing customers to directly submit samples for analysis, with flexible access models aimed at broadening adoption as Atera moves into commercial availability.

The platform also builds on 10x Genomics existing spatial biology ecosystem, particularly its Xenium solution, while expanding into large-scale data-driven applications. Bioptimus, a France-based AI biotech company, has partnered with 10x Genomics to develop one of the world’s largest spatial datasets under the STELA initiative to power its M-Optimus platform. The program will initially utilize Xenium, with plans to transition to Atera in 2027 as throughput scales. Management emphasized that Atera’s integrated system design significantly expands the scope of biological questions that can be addressed, positioning it as a key enabler of next-generation research and AI-driven drug discovery.

Adoption momentum is already taking shape among global service providers. Macrogen, along with its U.S. subsidiary Psomagen, has committed to deploying multiple Atera systems, becoming the first global service provider to adopt the platform. This investment reflects increasing demand for high-throughput, uncompromised spatial analysis in biopharma and translational research, positioning Macrogen to support large-scale programs and reinforcing early commercial traction for Atera.

Favorable Industry Prospect for TXGPer a report by Custom Market Insights, the global spatial biology market size is estimated at $1.48 billion in 2026 and is anticipated to reach $7.24 billion by 2035, expanding at a CAGR of 19.2% from 2026 to 2035.

Growth in spatial biology is driven by the rising demand for single-cell and tissue-level insights to better understand complex diseases like cancer. Expanding use in drug discovery, precision medicine and AI-driven research, along with advances in high-throughput sequencing technologies, is accelerating market adoption.

A Recent Development by TXGIn February, 10x Genomics announced that the PharosAI consortium, comprising four leading UK institutions, will leverage its Xenium platform to build one of the world’s most comprehensive multimodal cancer datasets. It will be backed by 18.9 million Euros in UK government funding, along with support from charities and industry partners, to power AI-driven models aimed at enabling earlier diagnosis, precision therapies and faster drug discovery.

TXG’s Zacks Rank & Other Key PicksCurrently, TXG sports a Zacks Rank #1 (Strong Buy).

Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .

Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.

GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.

Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.

, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, at 5:00 p.m. Pacific Time.

Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts

Investors: [email protected]

Media: [email protected]

SOURCE 10x Genomics, Inc.

, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.

Recent Updates

Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025. Launched Atera, a new platform to redefine how biology is measured and understood. Atera was engineered to deliver spatial whole-transcriptome analysis with single-cell sensitivity at unprecedented scale. The Company expects to start shipping Atera in the second half of 2026. Announced a partnership with Bioptimus, a global AI biotech company, to launch STELA, a multinational spatial data generation initiative to create foundational datasets connecting underlying biology with disease outcomes. The initiative is starting this effort on our Xenium platform and plans to expand to Atera over time. Ended the first quarter of 2026 with cash and cash equivalents and marketable securities of $539.8 million, representing a $112.9 million increase from March 31, 2025. "We had a solid start to the year, with double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables revenue," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The biggest highlight is our recent launch of Atera, which represents the most significant product introduction in our history. We are extremely encouraged by the extraordinary early customer response."

First Quarter 2026 Financial Results

Revenue was $150.8 million for the first quarter of 2026, a 3% decrease from the corresponding period of 2025. Excluding $16.8 million related to a patent litigation settlement recognized in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.

Gross margin was 70% for the first quarter of 2026, as compared to 68% for the corresponding prior year period. The increase in gross margin was primarily due to lower warranty costs and lower inventory write-downs, partially offset by a decrease in license and royalty revenue reflecting a non-recurring royalty benefit recognized in the first quarter of 2025.

Operating expenses were $123.2 million for the first quarter of 2026, a 15% decrease from $144.8 million for the corresponding prior year period. The decrease was primarily driven by lower outside legal expenses and personnel expenses, partially offset by a non-recurring gain on settlement of $9.2 million recognized in the first quarter of 2025.

Operating loss was $17.0 million for the first quarter of 2026, as compared to operating loss of $39.3 million for the corresponding prior year period.

Net loss was $13.5 million for the first quarter of 2026, as compared to a net loss of $34.4 million for the corresponding prior year period.

Cash and cash equivalents and marketable securities were $539.8 million as of March 31, 2026.

2026 Financial Guidance 

10x Genomics is maintaining its full year 2026 revenue guidance of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in 2025, this represents 0% to 4% growth over full year 2025.

Webcast and Conference Call Information

10x Genomics will host a conference call to discuss the first quarter 2026 financial results, business developments and outlook after market close on Thursday, May 7, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "outlook," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities and 10x Genomics, Inc.'s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company's quarterly report on Form 10-Q for the quarter ended March 31, 2026 to be filed with the U.S. Securities and Exchange Commission ("SEC"), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

Investors: [email protected]

Media: [email protected]

10x Genomics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended
March 31,

2026

2025

Products and services revenue

$      149,896

$      137,823

License and royalty revenue

947

17,060

Revenue (1)

150,843

154,883

Cost of products and services revenue (2)

44,665

49,438

Gross profit

106,178

105,445

Operating expenses:

Research and development (2)

56,847

64,245

Selling, general and administrative (2)

66,377

89,728

Gain on settlement

—

(9,200)

Total operating expenses

123,224

144,773

Loss from operations

(17,046)

(39,328)

Other income (expense):

Interest income

5,014

3,686

Other income (expense), net

(815)

2,136

Total other income

4,199

5,822

Loss before provision for income taxes

(12,847)

(33,506)

Provision for income taxes

623

852

Net loss

$      (13,470)

$      (34,358)

Net loss per share, basic and diluted

$         (0.10)

$         (0.28)

Weighted-average shares used to compute net loss per share, basic and diluted

128,291,153

122,606,091

__________________________

(1)

The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium and Xenium products:

Three Months Ended
March 31,

2026

2025

Instruments

Single Cell

$         5,223

$         5,913

Spatial

6,039

8,902

Total instruments revenue

11,262

14,815

Consumables

Single Cell

88,894

84,109

Spatial

40,907

31,247

Total consumables revenue

129,801

115,356

Services

8,833

7,652

Products and services revenue

149,896

137,823

License and royalty revenue

947

17,060

Total revenue

$      150,843

$      154,883

(1)

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

Three Months Ended
March 31,

2026

2025

Americas

United States*

$       76,693

$       86,818

Americas (excluding United States)

3,406

3,752

Total Americas

80,099

90,570

Europe, Middle East and Africa

36,852

31,895

Asia-Pacific

China

15,837

16,883

Asia-Pacific (excluding China)

18,055

15,535

Total Asia-Pacific

33,892

32,418

Total revenue

$      150,843

$      154,883

*

Includes license and royalty revenue.

(2)

Includes stock-based compensation expense as follows:

Three Months Ended
March 31,

(in thousands)

2026

2025

Cost of revenue

$         1,918

$         2,481

Research and development

10,695

14,106

Selling, general and administrative

10,029

14,489

Total stock-based compensation expense

$       22,642

$       31,076

10x Genomics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)

March 31,
2026

December 31,
2025

Assets

Current assets:

Cash and cash equivalents

$      490,285

$      473,966

Marketable securities

49,563

49,443

Accounts receivable, net

39,031

47,013

Other receivables

17,106

35,480

Inventory

53,487

56,341

Prepaid expenses and other current assets

20,261

22,208

Total current assets

669,733

684,451

Property and equipment, net

220,591

226,711

Operating lease right-of-use assets

58,390

60,450

Goodwill

4,511

4,511

Intangible assets, net

59,910

62,329

Other noncurrent assets

2,624

2,913

Total assets

$    1,015,759

$    1,041,365

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$       17,425

$       12,733

Accrued compensation and related benefits

21,506

42,500

Accrued expenses and other current liabilities

33,680

39,971

Deferred revenue

24,342

23,902

Operating lease liabilities

11,330

10,985

Contingent consideration, current

5,315

23,363

Total current liabilities

113,598

153,454

Contingent consideration, noncurrent

1,222

1,237

Operating lease liabilities, noncurrent

70,059

73,376

Deferred revenue, noncurrent

10,138

10,501

Other noncurrent liabilities

6,418

6,471

Total liabilities

201,435

245,039

Commitments and contingencies

Stockholders' equity:

Preferred stock

—

—

Common stock

2

2

Additional paid-in capital

2,338,269

2,306,690

Accumulated deficit

(1,524,061)

(1,510,591)

Accumulated other comprehensive income

114

225

Total stockholders' equity

814,324

796,326

Total liabilities and stockholders' equity

$    1,015,759

$    1,041,365

SOURCE 10x Genomics, Inc.

10x Genomics (TXG - Free Report) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +65.52%. A quarter ago, it was expected that this life science technology company would post a loss of $0.19 per share when it actually produced a loss of $0.13, delivering a surprise of +31.58%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

10x Genomics, which belongs to the Zacks Medical Info Systems industry, posted revenues of $150.84 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.57%. This compares to year-ago revenues of $154.88 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

10x Genomics shares have added about 39.4% since the beginning of the year versus the S&P 500's gain of 7.6%.

What's Next for 10x Genomics?While 10x Genomics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for 10x Genomics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.21 on $147.9 million in revenues for the coming quarter and -$0.82 on $611.56 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the bottom 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Lucid Diagnostics Inc. (LUCD - Free Report) , another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 15.

This company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of +68.8%. The consensus EPS estimate for the quarter has been revised 14.3% higher over the last 30 days to the current level.

Lucid Diagnostics Inc.'s revenues are expected to be $1.4 million, up 68.7% from the year-ago quarter.

Key Takeaways TXG beat Q1 estimates with a narrower loss and revenue growth excluding prior-year one-time items.10x Genomics grew consumables revenue 12.5% and expanded gross margin by 220 basis points.TXG maintained 2026 revenue guidance of $600M-$625M and ended Q1 with no debt. 10x Genomics (TXG - Free Report) delivered a loss per share of 10 cents in first-quarter 2026, narrower than the year-earlier loss per share of 36 cents. The figure surpassed the Zacks Consensus Estimate by 65.5%.

TXG's RevenuesTXG registered revenues of $150.8 million in the first quarter of 2026, which decreased about 2.6% year over year. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenues increased 9% year over year.  However, the figure surpassed the Zacks Consensus Estimate by 3.57%.

TXG’s Business Units in DetailThe company reports revenue under two primary segments: Products and Services and License and royalty revenue. 

Products and Services revenue totaled $149.9 million, up approximately 8.8% year over year. Within this segment, Total instruments revenues totaled $11.3 million, down 23.9% year over year. In contrast, Total consumables revenues were $129.8 million, representing a 12.5% year-over-year increase.

Services revenue totaled $8.8 million, up 15.4% year over year.

Meanwhile, License and royalty revenue was $0.9 million compared with $17.1 million in the prior-year quarter, which included $16.8 million related to one-time license and royalty revenue.

TXG's Geographical DistributionGeographically, 10x Genomics derives revenues from three major regions: the Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific. 

In the first quarter of 2026, Total Americas’ revenues were $80.1 million, reflecting a 11.6% year-over-year decline.

EMEA revenues totaled $36.9 million, up approximately 15.5% year over year.

Meanwhile, Total Asia-Pacific revenues were $33.9 million, representing 4.4% year-over-year growth.

TXG's Margin TrendIn the quarter under review, TXG’s gross profit improved 0.7% year over year to $106.2 million. The gross margin expanded 220 basis points (bps) to 70.3%.

Selling, general and administrative expenses fell 26% year over year to $66.4 million. Research and development expenses declined 11.5% year over year to $56.8 million. Total operating expenses of $123.2 million decreased 14.9% year over year.

Total operating loss was $17 million, reflecting an improvement from the prior-year loss of $39.3 million.

TXG’s Financial PositionTXG exited the first quarter of 2026 with cash, cash equivalents and marketable securities of $539.8 million, up from $523.4 million at the end of the fourth quarter of 2025. Importantly, the company ended the quarter with no debt on its balance sheet, underscoring a solid solvency position.

TXG’s 2026 Guidance10x Genomics has maintained its revenue outlook for 2026.

10x Genomics expects 2026 revenues to be in the range of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in 2026, this represents 0% to 4% growth over 2026.

Our Take10x Genomics exited the first quarter of 2026 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. While reported revenues declined year over year due to the absence of prior-year one-time license and royalty revenues, underlying business trends remained healthy, with Products and Services revenues rising on continued strength in consumables demand and higher services revenues. Growth across the EMEA and Asia-Pacific regions, expanding gross margin and disciplined cost controls were encouraging. The company also reported a significantly narrower operating loss year over year, supported by lower operating expenses and improving operating leverage.

During the quarter, 10x Genomics continued advancing its spatial biology and single-cell analysis portfolio through strategic innovation initiatives. The launch of Atera, its next-generation spatial whole-transcriptome platform designed to deliver single-cell sensitivity at unprecedented scale, marked a major technology milestone and is expected to support future growth following commercialization in the second half of 2026.

The company also partnered with Bioptimus to launch the STELA initiative, aimed at building foundational spatial datasets linking biology with disease outcomes using the Xenium platform, with planned expansion to Atera over time. Complementing these initiatives, TXG maintained a strong balance sheet with more than $539 million in cash and no debt, providing financial flexibility to support ongoing innovation and commercialization efforts.

TXG’s Zacks Rank and Stocks to ConsiderTXG currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space that are expected to report earnings soon are DexCom, Inc. (DXCM - Free Report) , Encompass Health Corporation (EHC - Free Report) and The Cooper Companies, Inc. (COO - Free Report) .

The Zacks Consensus Estimate for DexCom’s first-quarter 2026 adjusted earnings per share (EPS) is currently pegged at 47 cents. The consensus estimate for revenues is pegged at $1.18 billion. DXCM currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DexCom has an estimated long-term growth rate of 20.6%. DXCM’s earnings yield of 4.1% compares favorably with the industry’s negative yield.

Encompass Health currently has a Zacks Rank #2. The Zacks Consensus Estimate for its first-quarter 2026 adjusted EPS is currently pegged at $1.51. The same for revenues is pegged at $1.57 billion.

Encompass Health has an estimated long-term growth rate of 8.8%. EHC’s earnings yield of 5.9% compares favorably with the industry’s 5.6%.

Cooper Companies currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its second-quarter fiscal 2026 adjusted EPS is currently pegged at $1.10. The same for its revenues is pegged at $1.05 billion.

Cooper Companies has an estimated long-term growth rate of 8.4%. COO’s earnings yield of 7.2% compares favorably with the industry’s 6.1%.

Torex Gold Resources Inc. (TXG:CA) Q1 2026 Earnings Call Transcript

10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript

10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript

Key Takeaways 10x Genomics acquires Proteintech Genomics to expand proteomics and multiomics capabilities.TXG gains 4.8% after the deal, which adds protein-analysis tools compatible with Flex workflows.Proteintech technologies support combined RNA and protein analysis across single-cell platforms. 10x Genomics (TXG - Free Report) recently announced the acquisition of Proteintech Genomics, a division within Proteintech Group that develops high-plex proteomic solutions for single-cell and spatial biology applications. The move expands TXG's capabilities in proteomics and supports its broader strategy of advancing multiomics research through integrated RNA and protein analysis.

Proteintech Genomics brings technologies, including the Human Discovery Panel, an antibody-based single-cell protein panel compatible with 10x Genomics' Flex chemistry workflows. Management believes the acquisition will strengthen its single-cell and spatial biology platforms, while the company expects the transaction to have no meaningful impact on its near-term financial outlook.

Likely Trend of TXG Stock Following the NewsShares of TXG have gained 4.8% since the announcement in yesterday’s trading. In the year-to-date period, shares of the company have gained 87.6% against the industry’s 20.5% decline.  The S&P 500 increased 8.4% in the same time frame.

The acquisition is expected to strengthen TXG's long-term growth prospects by expanding its presence in the rapidly evolving proteomics market and enhancing its multiomics capabilities. By integrating Proteintech Genomics' protein-analysis technologies with its existing single-cell and spatial platforms, TXG can offer researchers a more comprehensive view of cellular biology through combined RNA and protein measurements. The deal also has the potential to increase customer adoption, drive higher consumables usage and improve platform stickiness, while positioning the company to capitalize on emerging opportunities in AI-driven biological modeling and next-generation life sciences research.

TXG currently has a market capitalization of $3.7 billion.

Image Source: Zacks Investment Research

More on the NewsThe acquisition significantly broadens 10x Genomics' proteomics portfolio by adding Proteintech Genomics' differentiated technologies, including the Human Discovery Panel, which the company describes as the largest antibody-based single-cell protein panel.

The panel is designed to support integrated analysis of intracellular proteins, cell-surface proteins and transcriptomic profiles within sequencing-compatible workflows. Importantly, the technology is already compatible with 10x Genomics' Flex chemistry, including the Flex Apex assay, enabling researchers to combine RNA and protein measurements within a unified workflow. Management believes that integrating transcriptomic and proteomic information at the single-cell and spatial levels will play an increasingly important role in advancing biological research and discovery.

The transaction also aligns with 10x Genomics' broader strategy of enabling multimodal biological analysis across its single-cell and spatial platforms. Proteintech Genomics' protein panels were purpose-built for 10x workflows and are already being used by researchers to simultaneously analyze RNA and protein expression. By bringing these capabilities in-house, TXG aims to simplify workflows that currently require multiple vendors and technologies to harmonize RNA and protein data.

The company also sees opportunities to extend these protein-analysis capabilities to its recently launched Atera platform. Researchers across fields such as immunology, oncology, neuroscience and cell biology are increasingly adopting combined transcriptomic and proteomic approaches to gain deeper insights into cellular identity, function and disease mechanisms, making the acquisition a strategic addition to TXG's long-term innovation roadmap.

Favorable Industry Prospect for TXGPer a report by Grand View Research, the global proteomics market size was valued at $38.4 billion in 2025 and is projected to grow beyond $97.7 billion by 2033, at a CAGR of 13.3%.

The market is witnessing significant growth driven by the rising prevalence of chronic and infectious diseases, growing preference for personalized medicine and the increasing demand for rapid & advanced diagnostic solutions in target disease treatment.

Recent Developments by TXGRecently, 10x Genomics exited the first quarter of 2026 on a solid note, with both earnings and revenues surpassing the Zacks Consensus Estimate. While total revenues declined year over year due to the absence of prior-year one-time license and royalty revenues, underlying business performance remained healthy, driven by higher consumables demand, increased services revenues, growth across the EMEA and Asia-Pacific regions, expanding gross margin and disciplined cost management.

The company also significantly narrowed its operating loss year over year. During the quarter, TXG strengthened its innovation pipeline with the launch of Atera, a next-generation spatial whole-transcriptome platform that offers single-cell sensitivity at scale and is expected to support growth following its planned commercialization in the second half of 2026.

TXG’s Zacks Rank & Key PicksCurrently, TXG carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.